Gene Therapy · us
Triglycerides Fall 63% After a Single CRISPR Infusion, as Early CTX310 Trial Shows Lipid-Lowering Signal
Ten patients with severe hypertriglyceridemia had substantial reductions in blood lipids within 30 days of receiving gene-editing therapy. Whether the effects can be sustained over the long term and reduce pancreatitis and cardiovascular events remains to be answered in larger studies.
For patients with severe hypertriglyceridemia, elevated blood lipids affect more than laboratory numbers; they also carry risks of acute pancreatitis and cardiovascular disease. An early human trial now points to a new possibility: using a single course of gene-editing therapy to reduce a protein involved in lipid metabolism and substantially lower triglycerides.
Cleveland Clinic announced on November 9 that the investigational therapy CTX310 reduced triglycerides by an average of 63% from pretreatment levels in 10 adult patients at day 30 after a single intravenous infusion. Results from this Phase 1b trial were presented at the American Heart Association’s annual meeting. The study was funded by the developer, CRISPR Therapeutics, and the findings remain early clinical evidence.
CTX310 uses CRISPR-Cas9 technology to inactivate the ANGPTL3 gene, which helps regulate lipid metabolism. The research team hopes this will provide sustained reductions in blood lipids and reduce the need for repeated dosing. Participants’ blood levels of ANGPTL3 protein fell by an average of approximately 65%, providing evidence, alongside the triglyceride changes, that the therapy was having an effect. However, short-term data cannot establish whether a single dose will deliver benefits lasting many years.
The developer’s announcement added that this was a multicenter, open-label trial, with participants’ median pretreatment triglyceride level exceeding 1,000 milligrams per deciliter. All 10 participants had diabetes, and 3 had a history of pancreatitis, indicating a substantial disease burden in this group. In addition to triglycerides, non-high-density lipoprotein cholesterol and apolipoprotein B also declined.
Regarding safety, as of the data cutoff, the study had reported no serious adverse events related to CTX310 and no clinically meaningful elevations in liver transaminases. One participant experienced a Grade 2 infusion-related reaction and completed the infusion after the reaction resolved. These findings provide preliminary information on tolerability, but a sample of 10 remains insufficient to rule out rare or delayed risks.
All participants completed at least 30 days of follow-up, and 7 had been followed for at least 90 days. The company said reductions in ANGPTL3 and triglycerides were maintained in those who reached 90 days of follow-up. However, this small, open-label study cannot yet establish an advantage over current treatments, and the average reduction does not mean every patient had the same response.
The next key question is whether lower blood lipids can translate into tangible health benefits for patients. Although no acute pancreatitis was reported during the trial, this does not establish that the therapy has reduced the risk of developing it. Larger studies and long-term follow-up are needed to clarify the durability and safety of gene editing, and whether it can reduce pancreatitis or cardiovascular events.